INTRODUCTION AND OBJECTIVES: Controversy still exists regarding the efficacy of testosterone replacement therapy (TRT) for symptomatic hypogonadism. A recent multi-site randomized controlled study of men undergoing TRT failed to show an improvement in several symptom domains, among them is vitality. We hypothesized that differences in androgen sensitivity would obscure symptom improvement for a subset of individuals. Androgen sensitivity is related to the number of trinucleotide (CAG) repeats on exon 1 of the androgen receptor (AR) gene. We sought to examine the regulatory role of this genetic polymorphism on the relationship between testosterone and vitality in middle-aged men METHODS: Participants were men from the Vietnam Era Twin Study of Aging (N¼696). Average waking, salivary free-testosterone level was acquired on 3 non-consecutive days. The AR gene CAG repeat length was derived using a combination of PCR fragment analysis and Sanger sequencing. Vitality was evaluated with the SF-36Vitality scale. We tested the interaction between low testosterone (low-T) and CAG repeat length while controlling for age, ethnicity, smoking status, BMI, heart disease, hypertension, diabetes, and the correlated nature of the twin data. Low-T was defined as being ¼ 1 SD below the mean for the 3-day average value RESULTS: Mean age of the participants was 56.4 years (SD ¼ 2.6) with average CAG repeat length of 22 (range: 8-37). We observed a significant interaction effect between low-T and AR CAG repeat length. In men with a short variant of the AR gene (< 21 repeats), representing greater androgen sensitivity, there was a significant effect of low-T on vitality (p < 0.01). Men with low-T and the short AR gene were on average 10 points lower on the Vitality scale relative to men with normal T and the same genotype. This effect was not observed in men with either medium (21-23 repeats) or long (¼ 24 repeats) variants of the AR gene. Without the interaction effect in the model, neither low-T nor the AR gene had a significant effect on vitality CONCLUSIONS: These results demonstrate that the relationship between low-T and vitality is regulated, in part, by variation in the AR gene. The effect of low-T on vitality was observed only when the genetically-determined sensitivity of the androgen receptor is at its greatest. Variations in the AR gene, bestowing differential androgen sensitivity, are potential targets for personalized therapy of hypogonadism. Future studies are needed to determine how genetic information can be used to improve the efficacy of TRT
INTRODUCTION AND OBJECTIVES: ED is a predictive risk factor for CVD. We monitored effectiveness and safety of long-term Testosterone Therapy (TTh) in hypogonadal men with a history of CVD. METHODS: Two observational registry studies of 622 hypogonadal men from two urological centers: 77 men with a previous diagnosis of coronary artery disease (CAD; n¼48) and/or a myocardial infarction (MI; n¼40) and/or stroke (n¼7) received TU for up to 8 years.
RESULTS: Mean age was 60.65 AE 4.98 years, mean follow-up time was 7.29 AE 1.20 years. Testosterone (T) levels rose from 9.78 AE 1.56 nmol/L to trough levels (measured prior to the following injection) between 16 and 18 nmol/L. IIEF-EF (maximum score: 30) increased from 19.64 AE 6.34 to 24.49 AE 4.69 with a change from baseline of 5.37AE0.36, this improvement was statistically significant for the first three years and remained statistically significant vs baseline throughout the observation time and stable compared to previous years. Weight decreased progressively from 114.47 AE 13.41 to 90.42 AE 8.77 by 23.6 AE 0.6 kg, proportion of weight loss: 19.62 AE 5.71%. Waist circumference decreased from 111.78AE8.22 to 99.24 AE 6.48 by 12.51 AE0.37 cm. The waist:height ratio improved from 0.64 AE 0.05 to 0.57 AE 0.04 (p<0.0001 for all). Blood pressure (BP, mmHg): Systolic BP decreased from 164.45 AE 14.4 to 132.96 AE 8.71, diastolic BP from 99.48 AE 11.37 to 76.39 AE 4.89, pulse pressure from 64.97 AE 6.48 to 56.57 AE 8.02 (p<0.0001 for all). Lipid pattern and glycaemic control improved significantly and sustainably. C-reactive protein (CRP) declined from 3.69 AE 4.51 to 0.25 AE 0.28 mg/dl. In no patient was testosterone therapy discontinued or interrupted. No cardiovascular events were reported during the observation time.
CONCLUSIONS: In hypogonadal men with a history of CVD, T therapy may improve and preserve erectile function for a prolonged period of time. No cardiologic or urologic events observed during entire period of T therapy. TTh appears to be well-tolerated and safe METHODS: This was a 24-week, randomized, parallel study of the clinical outcomes in men age > 40 years with symptomatic benign prostatic hypertrophy (BPH; International Prostate Symptom Score (IPSS) ! 12), prostate volume ! 30 mL, and testosterone level < 300 ng/dL with aging male symptoms, who were taking stable doses of alpha-blockers 4 weeks before participation. Eligible patients received a combination of dutasteride 0.5 mg once daily and a transdermal gel containing 10 g testosterone (T) (DT group, n¼30) or the transdermal gel alone (T group, n¼30). The primary outcomes were the change in the aging male symptom (AMS) score, sexual desire (question 17, AMS score), and erectile function (International Index of Erectile Function-5). Secondary outcomes were the post-treatment IPSS, peak urinary flow rate, post-void residual urine volume (PVR), and prostate volume.
RESULTS: Both groups showed significant improvements from baseline in all primary outcome parameters. However, there were no significant differences in the changes in the AMS total score (DT -5.2 vs. T -5.0; p¼0.55), sexual desire (DT -2.5 vs. T -2.3; p¼0.23), and IIEF-5 score (DT -2.1 vs. T -1.9; p¼0.13) between groups. The extent of IPSS improvement from baseline to 24 weeks was the same in both groups (DT -1.2 vs. T -1.0; p¼0.64). In addition, the changes in Q(max) and PVR from baseline were very similar in both groups. However, prostate volume decreased significantly (p<0.01) in the DT group (DT -2.1 cc vs. T +0.6 cc).
CONCLUSIONS: Concomitant dutasteride did not reduce the effect of testosterone replacement therapy in men with late-onset hypogonadism. Otherwise it would be helpful to prevent the progress of prostate size by TRT.
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